Immunotherapy for Infectious Diseases

232 Kilby and Bucy
21. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of
long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med
1995; 332:201–208.
22. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive
human immunodeficiency virus infection. N Engl J Med 1995; 332:209–216.
23. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility
complex genes on the course of HIV-1 infection. Nat Med 1996; 2:405–411.
24. Keet IP, Tang J, Klein MR, et al. Consistent associations of HLA class I and II and transporter
gene products with progression of HIV type 1 infection in homosexual men. J Infect
Dis 1999; 180:299–309.
25. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in
humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998;
4:1302–1307.
26. Ogg GS, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes
and plasma load of viral RNA. Science 1998; 279:2103–2106.
27. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ. Cytotoxic-T-cell responses,
viral load, and disease progression in early human immundeficiency virus 1 infection.
N Engl J Med 1997; 337:1267–1274.
28. Jin X, Bauer DE, Tuttleton SE, et al. Dramatic rise in plasma viremia after CD8(�) T cell
depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999;
189:991–998.
29. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency
virus infection by CD8(�) lymphocytes. Science 1999; 283:857–860.
30. Ho DD. Toward HIV eradication or remission: the tasks ahead. Science 1998;
280:1866–1867.
31. Bucy RP. Immune clearance of HIV-1 replication active cells: a model of two patterns of
steady state HIV infection. AIDS Res Hum Retroviruses 1999; 15:223–227.
32. Richman D. The challenge of immune control of immunodeficiency virus. J Clin Invest
1999; 104:677–678.
33. Fisher RA, Bertonis JM, Meier W. HIV infection is blocked in vitro by recombinant soluble
CD4. Nature 1988; 331:76–78.
34. Hussey RE, Richardson NE, Kowalski M. A soluble CD4 protein selectively inhibits HIV
replication and syncytium formation. Nature 1988; 331:78–81.
35. Deen KC, McDougal JS, Inacker R. A soluble form of CD4 (T4) protein inhibits AIDS
virus infection. Nature 1988; 331:82–84.
36. Traunecker A, Luke W, Karajalainen K. Soluble CD4 molecules neutralize HIV-1. Nature
1988; 331:84–86.
37. Kahn JO, Allan JD, Hodges TL. The safety and pharmacokinetics of recombinant soluble
CD4 (rCD4) in subjects with AIDS and AIDS-related complex. Ann Intern Med 1990;
112:254–261.
38. Baba M, Pauwels R, Balzarini J. Mechanisms of inhibitory effect of dextran sulfate and
heparin on replication of HIV in vitro. Proc Natl Acad Sci USA 1988; 85:6132–6136.
39. Baba M, Snoeck R, Pauwels R. Sulfated polysaccharides are potent and selective inhibitors
of various enveloped viruses, including HSV, CMV, VSV, and HIV. Antimicrob Agents
Chemother 1988; 32:1742–1745.
40. Mitsuya H, Looney DJ, Kuno S. Dextran sulfate suppression of viruses in the HIV family:
inhibition of virion binding to CD4� cells. Science 1988; 240:646–649.
41. Abrams DI, Kuno S, Wong R. Oral dextran sulfate (UA001) in the treatment of the
acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann Intern
Med 1989; 110:183–188.
42. Lorentsen KJ, Hendrix CW, Collins JM. Dextran sulfate is poorly absorbed after oral
administration. Ann Intern Med 1989; 111:561–566.